Jupiter Asset Management Ltd. Has $318,000 Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Jupiter Asset Management Ltd. lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 93.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 974 shares of the biopharmaceutical company’s stock after selling 13,636 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Alnylam Pharmaceuticals were worth $318,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the first quarter worth approximately $27,000. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $30,000. Ameritas Advisory Services LLC bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth $42,000. AlphaQuest LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $43,000. Finally, Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 87 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $449.16 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The company’s 50 day moving average price is $458.80 and its two-hundred day moving average price is $383.09. The stock has a market cap of $59.34 billion, a P/E ratio of -181.85 and a beta of 0.30. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 3,022 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the completion of the transaction, the executive vice president owned 20,221 shares in the company, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 15,650 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,675,409.21. This trade represents a 19.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 82,346 shares of company stock worth $37,530,942. Company insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ALNY. Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Evercore ISI upped their target price on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Royal Bank Of Canada raised their price target on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, September 19th. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Finally, Barclays increased their price objective on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $482.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.